

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2001 年 2 月 1 日 (01.02.2001)

PCT

(10) 国際公開番号
WO 01/07475 A1

(51) 国際特許分類: C07K 14/47, C12N 15/12,
I/21, C12P 21/02, C07K 16/18, A61K 38/18, A61P 5/06,
19/08, A61K 45/00, 48/00, G01N 33/53

(MATSUO, Hisayuki) [JP/JP]; 〒658-0073 兵庫県神戸市東灘区西岡本6丁目4-24, 204号 Hyogo (JP). 南竹義春 (MINAMITAKE, Yoshitaru) [JP/JP]; 〒370-0503 群馬県邑楽郡千代田町大字赤岩字くらかけ 2716番地1 サントリー株式会社 医薬センター内 Gunma (JP).

(21) 国際出願番号: PCT/JP00/04907

(22) 国際出願日: 2000 年 7 月 24 日 (24.07.2000)

(74) 代理人: 弁理士 岩谷 龍 (IWATANI, Ryo); 〒530-0003 大阪府大阪市北区堂島2丁目1番27号 桜橋千代田ビル5階 Osaka (JP).

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(81) 指定国 (国内): AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA.

(30) 優先権データ:
特願平11/210002 1999 年 7 月 23 日 (23.07.1999) JP
特願平11/338841

1999 年 11 月 29 日 (29.11.1999) JP

特願2000/126623 2000 年 4 月 26 日 (26.04.2000) JP

(84) 指定国 (広域): ARIPO 特許 (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) 出願人 および

(72) 発明者: 寒川賢治 (KANGAWA, Kenji) [JP/JP]; 〒562-0031 大阪府箕面市小野原東6丁目28、4-201号 Osaka (JP).

(72) 発明者: および

(75) 発明者/出願人 (米国についてのみ): 児島得康 (KOHJIMA, Masayasu) [JP/JP]; 〒560-0005 大阪府豊中市西緑丘1丁目5-1、302号 Osaka (JP). 細田洋司 (HOSODA, Hiroshi) [JP/JP]; 〒562-0034 大阪府箕面市西宿2丁目12-12 藤和箕面ホームズA808号 Osaka (JP). 松尾善之

添付公開書類:

— 国際調査報告書

2 文字コード及び他の略語については、定期発行される各 PCT ガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: NOVEL PEPTIDES

(54) 発明の名称: 新規ペプチド

(57) Abstract: Novel peptides compounds inducing the secretion of growth hormone. Peptide compounds or pharmaceutically acceptable salts thereof having an activity of elevating calcium ion concentration in cells which are characterized in that at least one amino acid has been substituted by a modified amino acid and/or a non-amino acid compound.

(57) 要約:

WO 01/07475 A1

成長ホルモンの分泌を誘導する新規ペプチド系化合物を提供する。
細胞内のカルシウムイオン濃度を上昇させる活性を有し、少なくとも一つのアミノ酸が修飾アミノ酸及び/又は非アミノ酸化合物により置換されたことを特徴とするペプチド系化合物又はその薬学的に許容される塩。

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

Scope of Claims


1. A peptide compound or pharmaceutically acceptable salt thereof with the following characteristics. At least one amino acid of a peptide having activity that increases the calcium ion concentration within a cell undergoes replacement using a modified amino acid and/or a non-amino acid compound.
2. (a) The peptide compound or pharmaceutically acceptable salt thereof described in Section 1 of the scope of claims containing an amino acid sequence which has (a) the amino acid sequence described in sequence 2 or (b) an amino acid sequence that extends from at least the amino terminal up to number 4 through number 10 in the sequence in question and, where at least one amino acid is missing from the section outside the amino acid sequence in question and to which an amino acid sequence has been substituted or added.
3. The peptide compound or pharmaceutically acceptable salt thereof described in Section 2 of the scope of claims having an amino acid sequence selected from a group composed of the amino acid sequences described in sequence numbers 3, 4, 5, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19, 22 and 23.
4. The peptide compound or pharmaceutically acceptable salt thereof described in Section 2 of the scope of claims having an amino acid sequence selected from a group composed of the amino acid sequences described in sequence numbers 25, 26, 29, 30, 31, 32, 34 and 35.
5. A peptide compound or a pharmaceutically acceptable salt thereof with the following characteristics. The activity of the peptide induces the secretion of growth hormone and increases the calcium ion concentration in a cell. In this peptide, (a) the constituent amino acids have either been modified or not and (b) there is at least one amino acid that has undergone substitution using a non-amino acid compound or not.
6. A peptide compound or pharmaceutically acceptable salt thereof with the following characteristics. The peptide compounds described in Sections 1 and 5 of the scope of claims having amino acid sequences described for sequence numbers 27, 28 and 33.

7. The peptide compound or pharmaceutically acceptable salt thereof described in Section 5 of the scope of claims with the following characteristics. It has (a) the amino acid sequence described in sequence number 2 or (b) at least the amino sequence from the amino terminal up to the number four through number ten amino acid sequences. For those sections outside the amino acid sequences from the amino terminal up to the number four through number ten amino acid sequences, it lacks at least one amino acid and contains an amino acid sequence that was substituted and/or added.

8. The peptide compound or pharmaceutically acceptable salt thereof described in Section 7 of the scope of claims with the following characteristics. It has one amino acid sequence selected from the group made up of the amino acid sequences described in sequence numbers 3, 4, 5, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19, 22 and 23.

9. The peptide compound or pharmaceutically acceptable salt thereof described in Section 7 of the scope of claims with the following characteristics. It has one amino acid sequence selected from the group made up of the amino acid sequences described in sequence numbers 25, 26, 29, 30, 31, 32, 34 and 35.

10. A peptide compound or pharmaceutically acceptable salt thereof described in Sections 1 and 5 of the scope of claims, where the section corresponding to the amino acid sequences from the number one of the amino terminal up to number four are expressed using the following formula.



Where A is an amino acid, a non-amino acid compound or is absent, and where B is an amino acid, a non-amino acid compound or is absent. (Note that molecular chain length "A + B" has a length corresponding to the peptide length.)

C and D may be the same or differ and they represent (a) a modified amino acid, (b) an amino acid with a hydrophobic side-chain or (c) an amino acid with a basic side-chain.

11. The peptide compound or pharmaceutically acceptable salt thereof described in Section 10 of the scope of claims with the following characteristics. "C" is either (a) a modified amino acid into which a saturated or unsaturated alkyl chain or chains having carbon numbers of one or more have been introduced into the alpha carbon of the amino acid through ester, ether, thioether, amide or disulfide bonds by using or not using alkaline groups having a carbon number of one or more, or (b) a modified amino acid into which a saturated or unsaturated alkyl chain with a carbon number of one or more has been introduced into the alpha carbon of the amino acid through ester, ether, thioether, amide or disulfide bonds by using or not using alkaline groups having a carbon number of one or more.

12. In the single amino acid sequence selected from the group made up of the amino acid sequences described in sequence numbers 2, 3, 9, 10, 11, 16, 17, 22, 25, 26, 27, 28, 29, 30 and 31, the section corresponding to the amino acid sequence from the amino terminal up to number one through number four is the peptide compound or pharmaceutically acceptable salt thereof which is the peptide compound described in Sections 10 or 11 of the scope of claims.

13. The peptide compound or pharmaceutically acceptable salt thereof described in Sections 1, 2, 3, 5, 7 or 8 of the scope of claims, in which the modified amino acid is the third amino acid from the amino terminal.

14. The peptide compound or pharmaceutically acceptable salt thereof described in Section 13 of the scope of claims with the following characteristics. The amino acid in the modified amino acid is either serine or cysteine.

15. The peptide compound or pharmaceutically acceptable salt thereof described in Sections 1, 2, 3, 5, 7 or 8 of the scope of claims, which contains a modified amino acid into which either (a) a saturated or unsaturated alkyl chain or chains having carbon numbers of one or more have been introduced into the alpha carbon of the amino acid through ester, ether, thioester, thioether, amide or carbamide bonds by using or not using alkylene groups having a carbon number of one or more, or (b) a modified amino acid into which a saturated or unsaturated alkyl chain with a carbon number of one or more or H has been introduced.

16. The amino acid into which the modified amino acid that is introduced to the alpha carbon of the amino acid is either (a) the saturated or unsaturated alkyl chain or chains having a carbon number of one through ester, ether, thioester, thioether, disulfide, amide, carbamide or thiocarbamide bonds either using or not using alkylene groups with a carbon number of one or more, or (b) the amino acid into which saturated or unsaturated alkyl chains having carbon numbers of one or more are introduced, which are the peptide compounds or pharmaceutically acceptable salts thereof described in Sections 1, 2, 4, 5, 6, 7, 9, 10 or 12.

17. The peptide compound or pharmaceutically acceptable salt thereof described in Sections 1, 2, 3, 5, 7 or 8 of the scope of claims that has a modified amino acid that has been modified by ester bonding.

18. The peptide compound or pharmaceutically acceptable salt thereof described in Sections 1, 2, 4, 5, 6, 7, 9, 10, 11 or 12 of the scope of claims, which contains a modified amino acid that was modified when the functional group of the side-chains of the amino acid formed ester bonds.

19. The peptide compound or pharmaceutically acceptable salt thereof described in Section 17 of the scope of claims, which has an amino acid in which the fatty acid has undergone an ester bond to the hydroxyl group of the side-chains of the amino acid.

20. The peptide compound or pharmaceutically acceptable salt thereof described in Section 18 of the scope of claims, which has an amino acid in which the fatty acid has undergone thioester bonding to the mercapto group or ester bonding to the hydroxyl group of the side-chains of the amino acid.

21. The peptide compound or pharmaceutically acceptable salt thereof described in Section 19 of the scope of claims, which has an amino acid in which bonded fatty acid has a carbon number from 2 to 35.

22. The peptide compound or pharmaceutically acceptable salt thereof described in Section 20 of the scope of claims, in which the fatty acid has a carbon number from 2 to 35.

23. The peptide compound or pharmaceutically acceptable salt thereof described in Section 21 of the scope of claims, which has

an amino acid in which the bonded fatty acid is selected from a group of fatty acids having carbon numbers of 2, 4, 6, 8, 10, 12, 14, 16 and 18.

24. The peptide compound or a pharmaceutically acceptable salt thereof described in Section 22 of the scope of claims, which is a fatty acid selected from a group composed of the fatty acids having carbon numbers of 2, 4, 6, 8, 10, 12, 14, 16 and 18.

25. The peptide compound or a pharmaceutically acceptable salt thereof described in Section 23 of the scope of claims in which the bonded fatty acid is an octanoic acid, its monoen fatty acid, or its polyen fatty acid.

26. The peptide compound or a pharmaceutically acceptable salt thereof described in Section 24 of the scope of claims in which the fatty acid is an octanoic acid, its monoen fatty acid, or its polyen fatty acid.

27. The peptide compound or a pharmaceutically acceptable salt thereof described in Section 23 of the scope of claims in which the bonded fatty acid is a decanoic acid, its monoen fatty acid, or its polyen fatty acid.

28. The peptide compound or a pharmaceutically acceptable salt thereof described in Section 24 of the scope of claims in which the fatty acid is a decanoic acid, its monoen fatty acid, or its polyen fatty acid.

29. A peptide compound with the following characteristics. Additional basic amino acids bond to the carboxyl terminal of the peptide compounds described in Sections 1 through 28 of the scope of claims.

30. The peptide compounds described in Sections 1, 2, 3, 5, 7, 8, 13, 14, 15, 17, 19, 21, 23, 25 and 27 of the scope of claims with the following characteristics. The amino terminal is modified using a saturated or unsaturated alkyl or acyl group with a carbon number of one or more and/or, the OH of the carboxyl group at the carboxyl terminal is OZ or NR₂R₃ (where Z is a pharmaceutically acceptable positive ion or a low-

grade branching chain or a non-branching chain alkyl group, and R2 and R3 are selected from a group made up of H and low-grade branching chains or non-branching chain alkyl groups, which may indicate groups identical to or different from each other).

31. The peptide compounds described in Sections 1, 2, 4, 5, 6, 7, 9, 10, 11, 12, 16, 18, 20, 22, 24, 26, 28 or 29 of the scope of claims with the following characteristics. The amino terminal amino group is modified by introducing a saturated or unsaturated alkyl or acyl group with a carbon number of one or more and/or, the OH of the carboxyl group at the carboxyl terminal is OZ or NR₂R₃ (where Z is a pharmaceutically acceptable positive ion or a low-grade branching chain or a non-branching chain alkyl group, and R2 and R3 are selected from a groups made up of H and low-grade branching chains or non-branching chain alkyl groups, which may indicate groups identical to or different from each other).

32. A peptide compound with the following characteristics. An additional basic group has been introduced to the amide inducer of the carboxyl terminal of the peptide compounds described in Sections 30 and 31 of the scope of claims.

33. A pharmaceutical compound having as its active ingredient the peptide compounds or pharmaceutically acceptable salts thereof described in Sections 1 through 32 of the scope of claims.

34. A pharmaceutical compound for the purpose of treating illnesses caused by a deficiency of or a decrease in growth hormone having, as its effective ingredient the peptide compounds or pharmaceutically acceptable salts thereof described in Sections 1 through 32 of the scope of claims.

35. A pharmaceutical compound for the purpose of treating illnesses not caused by a deficiency of or a decrease in growth hormones, containing the peptide compounds or pharmaceutically acceptable salts thereof described in Sections 1 through 32 of the scope of claims and a treatment agent pertaining to illnesses not caused by a deficiency of or a decrease in growth hormone.

36. The pharmaceutical compound described in Sections 33 through 35 of the scope of claims for the purpose of applications on non-human animals.

37. A method of treating illnesses caused by a deficiency of or a decrease in growth hormones involving

the administration of pharmaceutical compounds, the active ingredient of which is a peptide compound described in Sections 1 through 32 of the scope of claims or the pharmaceutically acceptable salts thereof.

38. An agent for treating illnesses not caused by a deficiency of or a decrease in growth hormone and a method of treating illnesses not caused by a deficiency of or a decrease in growth hormone involving the administration of pharmaceutical compounds containing a peptide compound or the pharmaceutically acceptable salts thereof, described in Sections 1 through 32 of the scope of claims.

39. Methods of treatment described in Sections 37 and 38 of the scope of claims for applications on non-human animals.

40. DNA that is encoded with amino acid sequences of the peptide compounds described in Sections 1 through 32 of the scope of claims, where the amino acid sequences coded into said DNA contain DNA that has basic sequences encoding peptides containing recognized sequences for which at least one amino acid is modifiable.

41. The DNA described in Section 40 of the scope of claims where one of the basic sequences is selected from a group made up of the basic sequences described in sequence numbers 6, 7, 14, 15, 20, 21, 24, 36, 37, 38, and 39.

42. The DNA described in Section 40 of the scope of claims where one of the basic sequences is selected from a group made up of the basic sequences described in sequence numbers 6, 7, 14, 15, 20, 21, 24, 36, 37, 38, and 39 and is a basic sequence encoded with amino acid.

43. A vector having the DNA described in Sections 40 through 42 of the scope of claims.

44. A cell containing the vector described in Section 43 of the scope of claims.

45. A cell capable of producing a peptide with at least one amino acid modified in the amino acid sequence, which is a peptide compound with a vector containing the DNA described in Sections 40 through 42 of the scope of claims as well as the amino acid sequence encoded in said DNA.

46. An antibody for the peptide compounds described in Sections 1 through 32 of the scope of claims.

47. A method of assaying the peptide compounds described in Sections 1 through 32 of the scope of claims with the following characteristics. The antibody described in Section 46 of the scope of claims is used to detect the peptide compounds described in Sections 1 through 32 of the scope of claims.

48. A detection kit for the peptide compounds described in Sections 1 through 32 of the scope of claims with the following characteristics. The antibody described in Section 46 of the scope of claims is used to detect the peptide compounds described in Sections 1 through 32 of the scope of claims.

49. A method of manufacturing the peptide compounds described in Sections 1 through 32 of the scope of claims consisting of collecting the desired peptide compounds from cell cultures that have undergone phenotypic transformations. In this manufacturing method, genetic manipulation is used on the peptide compounds described in Sections 1 through 32 of the scope of claims and host cells capable of modifying the side-chains of at least one amino acid in the peptide are transformed phenotypically using a vector containing the DNA described in Sections 40 through 42 of the scope of claims.

50. A method of manufacturing the peptide compounds described in Sections 1 through 32 of the scope of claims with the following characteristics. After collecting the desired substances from cell cultures that have been phenotypically transformed, select amino acids are modified chemically. In this manufacturing method, genetic manipulation is used on the peptide compounds described in Sections 1 through 32 of the scope of claims and host cells capable of modifying the side-chains of at least one amino acid in the peptide are transformed phenotypically using a vector containing the DNA described in Sections 40 through 42 of the scope of claims.

51. A method of manufacturing the peptide compounds described in Sections 19 through 28 of the scope of claims with the following characteristics. In the method of manufacturing the peptide compounds described in Sections 19 through 28 using genetic manipulation, cells are used which have activity that causes the fatty acids to undergo ester bonding with the hydroxyl groups of the side-chains of the amino acids or to undergo thioester bonding with the mercapto groups.

52. A method of manufacturing the peptide compounds described in Sections 19 through 28 of the scope of claims with the following characteristics. Cells are used having serine-acyl activity that cause fatty acids to

undergo ester bonding with the hydroxyl groups of the side-chains of the serine in the amino acid sequences described in sequence number 8.

53. A method of manufacturing the peptide compounds described in Sections 19 through 28 of the scope of claims with the following characteristics. Cells are used having acyl activity that cause the fatty acid to undergo ester bonding with the hydroxyl groups of the side-chains of the threonine in the amino acid sequence described in sequence number 28.

54. A pharmaceutical compound for the genetic treatment of illnesses caused by a decrease in or lack of growth hormone that works by manifesting peptides having at least one modified amino acid that has activity that increases the calcium ion concentration in the cell. This is accomplished by integrating a vector containing DNA that encodes the amino acid sequence of the peptide compounds described in Sections 1 through 32 of the scope of claims into the cell of the organism.

55. A method of treating illnesses caused by a decrease in or lack of growth hormone with the following characteristics. Peptides having activity that induces the secretion of growth hormones are manifested by integrating vectors containing the DNA that encodes the amino acid sequences of the peptide compounds described in Sections 1 through 32 of the scope of claims into the cells of the organism. The peptides containing the amino acid sequences encoded in said DNA are produced as peptides having recognized sequences in which at least one of the amino acids can be modified.

56. A pharmaceutical compound for the genetic treatment of illnesses that are not caused by a decrease in or lack of growth hormone. This is accomplished by integrating vectors containing DNA in which the amino acid sequences of the peptide compounds described in Sections 1 through 32 of the scope of claims are encoded into the cells of the organism. These have activity which increases the concentration of the calcium ions in the cells and peptides are manifested that have at least one modified amino acid.

57. A method of treating diseases not caused by a decrease in or lack of growth hormone with the following characteristics. Vectors containing the DNA that encodes the amino acid sequences of the peptide compounds described in Sections 1 through 32 of the scope of claims are integrated into the cells of an organism capable of producing as peptides, peptides having recognized sequences with at least one modifiable amino acid in the amino acid sequence in question. This allows the expression of peptides having activity that induces the secretion of growth hormone.

SEQUENCE LISTING

<110> Kangawa, Kenji

<120> New Peptides

<130> DS03F216

<150> JP 11-210002

<151> 1999-7-23

<150> JP 11-338841

<151> 1999-11-29

<150> JP 2000-126623

<151> 2000-4-26

<160> 39

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<223> Amino acid sequence for a core region of endogenous peptides of growth hormone secretagogue

<400>1

Gly Ser Ser Phe Leu Ser Pro

1

5

<210> 2

<211> 28

<212> PRT

<213> Rattus norvegicus

<223> Amino acid sequence for rat endogenous peptides of growth hormone secretagogue

<400> 2

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys

1

5

10

15

Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg

20

25

<210> 3

<211> 28

<212> PRT

2/25

<213> Homo sapiens

<223> Amino acid sequence for human endogenous peptides of growth hormone secretagogue

<400>3

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys
1 5 10 15
Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg
20 25

<210> 4

<211> 117

<212> PRT

<213> Rattus norvegicus

<223> Amino acid sequence for a prepro-form of rat endogenous peptides of growth hormone secretagogue

<400>4

Met Val Ser Ser Ala Thr Ile Cys Ser Leu Leu Leu Leu Ser Met Leu
1 5 10 15
Trp Met Asp Met Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His
20 25 30
Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu
35 40 45
Gln Pro Arg Ala Leu Glu Gly Trp Leu His Pro Glu Asp Arg Gly Gln
50 55 60
Ala Glu Glu Ala Glu Glu Glu Leu Glu Ile Arg Phe Asn Ala Pro Phe
65 70 75 80
Asp Val Gly Ile Lys Leu Ser Gly Ala Gln Tyr Gln Gln His Gly Arg
85 90 95
Ala Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Val Lys Glu
100 105 110
Ala Pro Ala Asn Lys
115

<210> 5

<211> 117

<212> PRT

<213> Homo sapiens

<223> Amino acid sequence for prepro-form of human endogenous peptides of growth hormone secretagogue

<400> 5

```

Met Pro Ser Pro Gly Thr Val Cys Ser Leu Leu Leu Leu Gly Met Leu
  1             5             10            15
Trp Leu Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His
          20             25             30
Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu
          35             40             45
Gln Pro Arg Ala Leu Ala Gly Trp Leu Arg Pro Glu Asp Gly Gly Gln
          50             55             60
Ala Glu Gly Ala Glu Asp Glu Leu Glu Val Arg Phe Asn Ala Pro Phe
          65             70             75             80
Asp Val Gly Ile Lys Leu Ser Gly Val Gln Tyr Gln Gln His Ser Gln
          85             90             95
Ala Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Ala Lys Glu
          100            105            110
Ala Pro Ala Asp Lys
          115

```

<210> 6

<211> 501

<212> cDNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (31)... (381)

<223> Base sequence of cDNA coding prepro-form of rat endogenous peptides of growth hormone secretagogue

<400> 6

```

tccagatcat ctgtctctcac caccaaggcc atg gtg tct tca gcg act          48
                      Met Val Ser Ser Ala Thr
                      1             5
atc tgc agt ttg cta ctc ctc agc atg ctc tgg atg gac atg gcc atg      96
Ile Cys Ser Leu Leu Leu Leu Ser Met Leu Trp Met Asp Met Ala Met

```

4/25

10	15	20	
gca ggt tcc agc ttc ttg agc cca gag cac cag aaa gcc cag cag aga	144		
Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg			
25	30	35	
aag gaa tcc aag aag cca cca gct aaa ctg cag cca cga gct ctg gaa	192		
Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg Ala Leu Glu			
40	45	50	
ggc tgg ctc cac cca gag gac aga gga caa gca gaa gag gca gag gag	240		
Gly Trp Leu His Pro Glu Asp Arg Gly Gln Ala Glu Glu Ala Glu Glu			
55	60	65	70
gag ctg gaa atc agg ttc aat gct ccc ttc gat gtt ggc atc aag ctg	288		
Glu Leu Glu Ile Arg Phe Asn Ala Pro Phe Asp Val Gly Ile Lys Leu			
75	80	85	
tca gga gct cag tac cag cag cat ggc cgg gcc ctg gga aag ttt ctt	336		
Ser Gly Ala Gln Tyr Gln Gln His Gly Arg Ala Leu Gly Lys Phe Leu			
90	95	100	
cag gat atc ctc tgg gaa gag gtc aaa gag gcg cca gct aac aag	381		
Gln Asp Ile Leu Trp Glu Glu Val Lys Glu Ala Pro Ala Asn Lys			
105	110	115	
taaccactga caggactggc cccigtactt tctctctaag caagaactca catccagctt	441		
ctgcctcctc tgcaactccc agcactctcc tgcigactta caaataaatg ttcaagctgt	501		

<210> 7

<211> 511

<212> DNA

<220>

<221> CDS

<222> (34)... (384)

<213> Homo sapiens

<223> Base sequence of cDNA coding prepro-form of human endogenous peptides
of growth hormone secretagogue

<400>7

gcaggccac ctgtctgcaa cccagctgag gcc atg ccc tcc cca	45
Met Pro Ser Pro	
1	
ggg acc gtc tgc agc ctc ctg ctc ctc ggc atg ctc tgg ctg gac ttg	93

Gly Thr Val Cys Ser Leu Leu Leu Leu Gly Met Leu Trp Leu Asp Leu
 5 10 15 20
 gcc atg gca ggc tcc agc ttc ctg agc cct gaa cac cag aga gtc cag 141
 Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln
 25 30 35
 cag aga aag gag tcg aag aag cca cca gcc aag ctg cag ccc cga gct 189
 Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg Ala
 40 45 50
 cta gca ggc tgg ctg cgc cgg gaa gat gga ggt caa gca gaa ggg gca 237
 Leu Ala Gly Trp Leu Arg Pro Glu Asp Gly Gly Gln Ala Glu Gly Ala
 55 60 65
 gag gat gaa ctg gaa gtc cgg ttc aac gcc ccc ttt gat gtt gga atc 285
 Glu Asp Glu Leu Glu Val Arg Phe Asn Ala Pro Phe Asp Val Gly Ile
 70 75 80
 aag ctg tca ggg gtt cag tac cag cag cac agc cag gcc ctg ggg aag 333
 Lys Leu Ser Gly Val Gln Tyr Gln Gln His Ser Gln Ala Leu Gly Lys
 85 90 95 100
 ttt ctt cag gac atc ctg tgg gaa gag gcc aaa gag gcc cca gcc gac 381
 Phe Leu Gln Asp Ile Leu Trp Glu Glu Ala Lys Glu Ala Pro Ala Asp
 105 110 115
 aag tgatgccca caagccttac tcacctctct ctaagttag aagcgctcat 434
 Lys

 ctggcttttc gcttgcttct gcagcaactc ccagcactgt tgtacaagct caggaggcga 494
 ataaatgctc aaactgt 511

<210> 8

<211> 4

<212> PRT

<213> Artificial Sequence

<223> Amino acid sequence for a core region of endogenous peptides of growth
 hormone secretagogue

<400> 8

Gly Ser Ser Phe

6/25

<210> 9

<211> 10

<212> PRT

<213> Artificial Sequence

<223> Amino acid sequence for a core region of endogenous peptides of growth hormone secretagogue

<400> 9

Gly Ser Ser Phe Leu Ser Pro Glu His Gln

1

5

10

<210> 10

<211> 27

<212> PRT

<213> Rattus norvegicus

<223> Amino acid sequence for rat endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 10

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Ala Gln Arg Lys Glu

1

5

10

15

Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg

20

25

<210> 11

<211> 27

<212> PRT

<213> Homo sapiens

<223> Amino acid sequence for human endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 11

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln Arg Lys Glu

1

5

10

15

Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg

20

25

<210> 12

<211> 116

7/25

<212> PRT

<213> Rattus norvegicus

<223> Amino acid sequence for a prepro-form of rat endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 12

Met Val Ser Ser Ala Thr Ile Cys Ser Leu Leu Leu Leu Ser Met Leu
1 5 10 15
Trp Met Asp Met Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His
20 25 30
Gln Lys Ala Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln
35 40 45
Pro Arg Ala Leu Glu Gly Trp Leu His Pro Glu Asp Arg Gly Gln Ala
50 55 60
Glu Glu Ala Glu Glu Glu Leu Glu Ile Arg Phe Asn Ala Pro Phe Asp
65 70 75 80
Val Gly Ile Lys Leu Ser Gly Ala Gln Tyr Gln Gln His Gly Arg Ala
85 90 95
Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Val Lys Glu Ala
100 105 110
Pro Ala Asn Lys
115

<210> 13

<211> 116

<212> PRT

<213> Homo sapiens

<223> Amino acid sequence for prepro-form of human endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 13

Met Pro Ser Pro Gly Thr Val Cys Ser Leu Leu Leu Leu Gly Met Leu
1 5 10 15
Trp Leu Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His
20 25 30
Gln Arg Val Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln
35 40 45
Pro Arg Ala Leu Ala Gly Trp Leu Arg Pro Glu Asp Gly Gly Gln Ala

50 55 60
 Glu Gly Ala Glu Asp Glu Leu Glu Val Arg Phe Asn Ala Pro Phe Asp
 65 70 75 80
 Val Gly Ile Lys Leu Ser Gly Val Gln Tyr Gln Gln His Ser Gln Ala
 85 90 95
 Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Ala Lys Glu Ala
 100 105 110
 Pro Ala Asp Lys
 115

〈210〉 14

<211> 498

<212> cDNA

〈213〉 *Rattus norvegicus*

<220>

<221> CDS

〈222〉 (31)... (378)

<223> Base sequence of cDNA coding prepro-form of rat endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 14

lccagatcat ctgicctcac caccaaggcc atg gig tct tca gcg act	48
Met Val Ser Ser Ala Thr	
1 5	
atc tgc agt ttg cta ctc ctc agc atg ctc tgg atg gac atg gcc atg	96
Ile Cys Ser Leu Leu Leu Ser Met Leu Trp Met Asp Met Ala Met	
10 15 20	
gca ggi tcc agc ttc ttg agc cca gag cac cag aaa gcc cag aga aag	144
Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Ala Gln Arg Lys	
25 30 35	
gaa tcc aag aag cca cca gct aaa ctg cag cca cga gct ctg gaa ggc	192
Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg Ala Leu Glu Gly	
40 45 50	
tgg ctc cac cca gag gac aga gga caa gca gaa gag gca gag gag gag	240
Trp Leu His Pro Glu Asp Arg Gly Gln Ala Glu Glu Ala Glu Glu Glu	
55 60 65 70	
ctg gaa atc agg ttc aat gct ccc ttc gat gtt ggc atc aag ctg tca	288

9/25

Leu Glu Ile Arg Phe Asn Ala Pro Phe Asp Val Gly Ile Lys Leu Ser
 75 80 85
 gga gct cag tac cag cag cat ggc cgg gcc ctg gga aag ttt ctt cag 336
 Gly Ala Gln Tyr Gln Gln His Gly Arg Ala Leu Gly Lys Phe Leu Gln
 90 95 100
 gat atc ctc tgg gaa gag gtc aaa gag gcg cca gct aac aag 378
 Asp Ile Leu Trp Glu Glu Val Lys Glu Ala Pro Ala Asn Lys
 105 110 115
 taaccacitga caggacitgtt cccigtactt tccctctaag caagaactca catccagctt 438
 ctgcctcttc tgaactctcc agcactctcc tgcctgactta caaataaatg ttcaagctgt 498

<210> 15

<211> 508

<212> DNA

<220>

<221> CDS

<222> (34)... (381)

<213> Homo sapiens

<223> Base sequence of cDNA coding prepro-form of human endogenous peptides
 (27 amino acids) of growth hormone secretagogue

<400> 15

gcaggccac ctgtctgcaa cccagctgag gcc atg ccc tcc cca 45
 Met Pro Ser Pro
 1
 ggg acc gtc tgc agc ctc ctg ctc ctc ggc atg ctc tgg ctg gac ttg 93
 Gly Thr Val Cys Ser Leu Leu Leu Leu Gly Met Leu Trp Leu Asp Leu
 5 10 15 20
 gcc atg gca ggc tcc agc ttc ctg agc cct gaa cac cag aga gtc cag 141
 Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln
 25 30 35
 aga aag gag tcg aag aag cca cca gcc aag ctg cag ccc cga gct cta 189
 Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg Ala Leu
 40 45 50
 gca ggc tgg ctc cgc ccg gaa gat gga ggt caa gca gaa ggg gca gag 237
 Ala Gly Trp Leu Arg Pro Glu Asp Gly Gly Gln Ala Glu Gly Ala Glu
 55 60 65

10/25

gat gaa ctg gaa gtc cgg ttc aac gcc ccc ttt gat gtt gga atc aag 285
Asp Glu Leu Glu Val Arg Phe Asn Ala Pro Phe Asp Val Gly Ile Lys
70 75 80
ctg tca ggg gtt cag tac cag cag cac agc cag gcc ctg ggg aag ttt 333
Leu Ser Gly Val Gln Tyr Gln Gln His Ser Gln Ala Leu Gly Lys Phe
85 90 95 100
ctt cag gac atc ctc tgg gaa gag gcc aaa gag gcc cca gcc gac aag 381
Leu Gln Asp Ile Leu Trp Glu Glu Ala Lys Glu Ala Pro Ala Asp Lys
105 110 115
tgatcgccca caagccttac tcacctctct ctaagttag aagcgctcat 431
ctggtttttc gcttgccttc gcagcaactc ccacgactgt tglacaagct caggaggcga 491
ataaatgttc aaacigt 508

<210> 16

<211> 28

<212> PRT

<213> Sus scrofa (pig)

<223> Amino acid sequence for porcine endogenous peptides of growth hormone secretagogue

<400> 16

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys
1 5 10 15
Glu Ser Lys Lys Pro Ala Ala Lys Leu Lys Pro Arg
20 25

<210> 17

<211> 27

<212> PRT

<213> Sus scrofa (pig)

<223> Amino acid sequence for porcine endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 17

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Val Gln Arg Lys Glu
1 5 10 15
Ser Lys Lys Pro Ala Ala Lys Leu Lys Pro Arg

11/25

20

25

<210> 18

<211> 118

<212> PRT

<213> Sus scrofa (pig)

<223> Amino acid sequence for prepro-form of porcine endogenous peptides of growth hormone secretagogue

<400> 18

Met Pro Ser Thr Gly Thr Ile Cys Ser Leu Leu Leu Ser Val Leu
 1 5 10 15
 Leu Met Ala Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu
 20 25 30
 His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Ala Ala Lys
 35 40 45
 Leu Lys Pro Arg Ala Leu Glu Gly Trp Leu Gly Pro Glu Asp Ser Gly
 50 55 60
 Glu Val Glu Gly Thr Glu Asp Lys Leu Glu Ile Arg Phe Asn Ala Pro
 65 70 75 80
 Cys Asp Val Gly Ile Lys Leu Ser Gly Ala Gln Ser Asp Gln His Gly
 85 90 95
 Gln Pro Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Val Thr
 100 105 110
 Glu Ala Pro Ala Asp Lys
 115

<210> 19

<211> 117

<212> PRT

<213> Sus scrofa (pig)

<223> Amino acid sequence for prepro-form of porcine endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 19

Met Pro Ser Thr Gly Thr Ile Cys Ser Leu Leu Leu Ser Val Leu
 1 5 10 15
 Leu Met Ala Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu

12/25

20 25 30
 His Gln Lys Val Gln Arg Lys Glu Ser Lys Lys Pro Ala Ala Lys Leu
 35 40 45
 Lys Pro Arg Ala Leu Glu Gly Trp Leu Gly Pro Glu Asp Ser Gly Glu
 50 55 60
 Val Glu Gly Thr Glu Asp Lys Leu Glu Ile Arg Phe Asn Ala Pro Cys
 65 70 75 80
 Asp Val Gly Ile Lys Leu Ser Gly Ala Gln Ser Asp Gln His Gly Gln
 85 90 95
 Pro Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu Val Thr Glu
 100 105 110
 Ala Pro Ala Asp Lys
 115

<210> 20

<211> 494

<212> DNA

<220>

<221> CDS

<222> (9)... (362)

<213> Sus scrofa (pig)

<223> Base sequence of cDNA coding prepro-form of porcine endogenous peptides of growth hormone secretagogue

<400> 20

ctgaggcc atg ccc tcc acg ggg acc att tgc agc ctg ctg ctc ctc 47
 Met Pro Ser Thr Gly Thr Ile Cys Ser Leu Leu Leu Leu
 1 5 10
 agc glg ctc ctc atg gca gac ttg gcc atg gcg ggc tcc agc ttc ttg 95
 Ser Val Leu Leu Met Ala Asp Leu Ala Met Ala Gly Ser Ser Phe Leu
 15 20 25
 agc ccc gaa cac cag aaa gtg cag cag aga aag gag tcc aag aag cca 143
 Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro
 30 35 40 45
 gca gcc aaa ctg aag ccc cgg gcc ctg gaa ggc tgg ctc ggc cca gaa 191
 Ala Ala Lys Leu Lys Pro Arg Ala Leu Glu Gly Trp Leu Gly Pro Glu
 50 55 60

13/25

gac agt ggt gag gtg gaa ggc acg gag gac aag ctg gaa atc cgg ttc 239
 Asp Ser Gly Glu Val Glu Gly Thr Glu Asp Lys Leu Glu Ile Arg Phe
 65 70 75
 aac gcc ccc tgt gat gtt ggg atc aag ttg tca ggg gct cag tcc gac 287
 Asn Ala Pro Cys Asp Val Gly Ile Lys Leu Ser Gly Ala Gln Ser Asp
 80 85 90
 cag cac ggc cag ccc ctg ggg aaa ttt ctc cag gac atc ctc tgg gaa 335
 Gln His Gly Gln Pro Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu
 95 100 105
 gag gtc act gag gcc ccg gcc gac aag tgatgtcccc tgagaccagc 382
 Glu Val Thr Glu Ala Pro Ala Asp Lys
 110 115

caccctcgtt cccccagct cctaagggct caccctggctt ccaggacgct tccactatca 442
 caccagctc tgagggatgc tagcctggga ggtgaataaa caticagact gg 494

<210> 21

<211> 491

<212> DNA

<220>

<221> CDS

<222> (9)... (359)

<213> Sus scrofa (pig)

<223> Base sequence of cDNA coding prepro-form of porcine endogenous
 peptides (27 amino acids) of growth hormone secretagogue

<400> 21

ctgaggcc atg ccc tcc acg ggg acc att tgc agc ctg ctg ctc ctc 47
 Met Pro Ser Thr Gly Thr Ile Cys Ser Leu Leu Leu Leu
 1 5 10
 agc gtg ctc ctc atg gca gac ttg gcc atg gcg ggc tcc agc ttc ttg 95
 Ser Val Leu Leu Met Ala Asp Leu Ala Met Ala Gly Ser Ser Phe Leu
 15 20 25
 agc ccc gaa cac cag aaa glg cag aga aag gag tcc aag aag cca gca 143
 Ser Pro Glu His Gln Lys Val Gln Arg Lys Glu Ser Lys Lys Pro Ala
 30 35 40 45
 gcc aaa ctg aag ccc cgg gcc ctg gaa ggc tgg ctc ggc cca gaa gac 191

Ala Lys Leu Lys Pro Arg Ala Leu Glu Gly Trp Leu Gly Pro Glu Asp
 50 55 60
 agt ggt gag gtg gaa ggc acg gag gac aag ctg gaa atc cgg ttc aac 239
 Ser Gly Glu Val Glu Gly Thr Glu Asp Lys Leu Glu Ile Arg Phe Asn
 65 70 75
 gcc ccc tgt gat gtt ggg atc aag ttg tca ggg gct cag tcc gac cag 287
 Ala Pro Cys Asp Val Gly Ile Lys Leu Ser Gly Ala Gln Ser Asp Gln
 80 85 90
 cac ggc cag ccc ctg ggg aaa ttt ctc cag gac atc ctc tgg gaa gag 335
 His Gly Gln Pro Leu Gly Lys Phe Leu Gln Asp Ile Leu Trp Glu Glu
 95 100 105
 gtc act gag gcc ccg gcc gac aag tgattgiccc tgagaccagc 379
 Val Thr Glu Ala Pro Ala Asp Lys
 110 115

cacctctgtt ctcccagcct cctaagggtt cacciggttt ccaggacgtt tccactatca 439
 caccagcttc tgagggaatgc tagcctggga ggtgaataaaa cattcagact gg 491

<210> 22

<211> 27

<212> PRT

<213> Bos taurus

<223> Amino acid sequence for bovine endogenous peptides (27 amino acids)
 of growth hormone secretagogue

<400> 22

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Glu Leu Gln Arg Lys Glu
 1 5 10 15

Ala Lys Lys Pro Ser Gly Arg Leu Lys Pro Arg
 20 25

<210> 23

<211> 89

<212> PRT

<213> Bos taurus

<223> Partial amino acid sequence for a prepro-form of bovine endogenous
 peptides (27 amino acids) of growth hormone secretagogue

15/25

<400> 23

Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Glu
 1 5 10 15
 Leu Gln Arg Lys Glu Ala Lys Lys Pro Ser Gly Arg Leu Lys Pro Arg
 20 25 30
 Thr Leu Glu Gly Gln Phe Asp Phe Glu Val Gly Ser Gln Ala Glu Gly
 35 40 45
 Ala Glu Asp Glu Leu Glu Ile Arg Phe Asn Ala Phe Phe Asn Ile Gly
 50 55 60
 Ile Lys Leu Ala Gly Ala Gln Ser Leu Gln His Gly Gln Thr Leu Gly
 65 70 75 80
 Lys Phe Leu Gln Asp Ile Leu Trp Glu
 85

<210> 24

<211> 267

<212> DNA

<220>

<221> CDS

<222> (1)... (267)

<213> Bos taurus

<223> Base sequence of cDNA coding prepro-form of bovine endogenous peptides (27 amino acids) of growth hormone secretagogue

<400> 24

gac ttg gcc atg gcg ggc tcc agc ttt ctg agc ccc gaa cat cag gaa 48
 Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro Glu His Gln Glu
 1 5 10 15
 ctg cag aga aag gaa gct aag aag cca tca ggc aga ctg aag ccc cgg 96
 Leu Gln Arg Lys Glu Ala Lys Lys Pro Ser Gly Arg Leu Lys Pro Arg
 20 25 30
 acc ctg gaa ggc cag ttt gac ccg gag gtg gga agt cag gcg gaa ggt 144
 Thr Leu Glu Gly Gln Phe Asp Phe Glu Val Gly Ser Gln Ala Glu Gly
 35 40 45
 gca gag gac gag ctg gaa atc cgg ttc aac gcc ccc ttt aac att ggg 192
 Ala Glu Asp Glu Leu Glu Ile Arg Phe Asn Ala Phe Phe Asn Ile Gly
 50 55 60

16/25

atc aag cta gca ggg gct cag tcc ctc cag cat ggc cag acg ttg ggg 240
 Ile Lys Leu Ala Gly Ala Gln Ser Leu Gln His Gly Gln Thr Leu Gly
 65 70 75 80
 aag ttt ctt cag gac atc ctc tgg gaa 267
 Lys Phe Leu Gln Asp Ile Leu Trp Glu
 85

<210> 25

<211> 24

<212> PRT

<213> *Gallus domesticus*

<223> Amino acid sequence for chicken endogenous peptides of growth hormone
secretagogue

<400> 25

Gly Ser Ser Phe Leu Ser Pro Thr Tyr Lys Asn Ile Gln Gln Gln Lys
 1 5 10 15
 Gly Thr Arg Lys Pro Thr Ala Arg
 20

<210> 26

<211> 21

<212> PRT

<213> *Anguilla japonica*

<220>

<221> AMIDATION

<222> 21

<223> Amino acid sequence for eel endogenous peptides of growth hormone
secretagogue

<400> 26

Gly Ser Ser Phe Leu Ser Pro Ser Gln Arg Pro Gln Gly Lys Asp Lys
 1 5 10 15
 Lys Pro Pro Arg Val
 20

<210> 27

<211> 28

17/25

<212> PRT

<213> Rana cafesbeiana

<223> Amino acid sequence for frog endogenous peptides of growth hormone secretagogue

<400> 27

Gly Leu Ser Phe Leu Ser Pro Ala Glu Met Gln Lys Ile Ala Glu Arg
1 5 10 15

Gln Ser Gln Asn Lys Leu Arg His Gly Asn Met Arg
20 25

<210> 28

<211> 27

<212> PRT

<213> Xenopus laevis

<223> Amino acid sequence for frog (Xenopus laevis) endogenous peptides of growth hormone secretagogue

<400> 28

Gly Leu Thr Phe Leu Ser Pro Ala Asp Met Gln Lys Ile Ala Glu Arg
1 5 10 15

Gln Ser Gln Asn Lys Leu Arg His Gly Asn Met
20 25

<210> 29

<211> 23

<212> PRT

<213> Oncorhynchus mykiss

<220>

<221>AMIDATION

<222> 23

<223> Amino acid sequence for rainbow trout endogenous peptides (23 amino acids) of growth hormone secretagogue

<400> 29

Gly Ser Ser Phe Leu Ser Pro Ser Gln Lys Pro Gln Val Arg Gln Gly
1 5 10 15

Lys Gly Lys Pro Pro Arg Val
20

<210> 30

<211> 20

<212> PRT

<213> *Oncorhynchus mykiss*

<220>

<221> AMIDATION

<222> 20

<223> Amino acid sequence for rainbow trout endogenous peptides (20 amino acids) of growth hormone secretagogue

<400> 30

Gly Ser Ser Phe Leu Ser Pro Ser Gln Lys Pro Gln Gly Lys Gly Lys

1 5 10 15

Pro Pro Arg Val

20

<210> 31

<211> 28

<212> PRT

<213> *Canis familiaris*

<223> Amino acid sequence for dog endogenous peptides of growth hormone secretagogue

<400> 31

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Leu Gln Gln Arg Lys

1 5 10 15

Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg

20 25

<210> 32

<211> 108

<212> PRT

<213> *Anguilla japonica*

<223> Amino acid sequence for prepro-form of eel endogenous peptides of growth hormone secretagogue

<400> 32

Met Lys Arg Thr Ala Tyr Ile Ile Leu Leu Val Cys Val Leu Ala Leu

19/25

1 5 10 15
 Trp Met Asp Ser Val Gln Ala Gly Ser Ser Phe Leu Ser Pro Ser Gln
 20 25 30
 Arg Pro Gln Gly Lys Asp Lys Lys Pro Pro Arg Val Gly Arg Arg Asp
 35 40 45
 Ser Asp Gly Ile Leu Asp Leu Phe Met Arg Pro Pro Leu Gln Asp Glu
 50 55 60
 Asp Ile Arg His Ile Thr Phe Asn Thr Pro Phe Glu Ile Gly Ile Thr
 65 70 75 80
 Met Thr Glu Glu Leu Phe Gln Gln Tyr Gly Glu Val Met Gln Lys Ile
 85 90 95
 Met Gln Asp Leu Leu Met Asp Thr Pro Ala Lys Glu
 100 105

<210> 33

<211> 114

<212> PRT

<213> *Xenopus laevis*

<223> Amino acid sequence frog (*Xenopus laevis*) endogenous peptides of growth hormone secretagogue

<400>33

Met Asn Phe Gly Lys Ala Ala Ile Phe Gly Val Val Leu Phe Cys Leu
 1 5 10 15
 Leu Trp Thr Glu Gly Ala Gln Ala Gly Leu Thr Phe Leu Ser Pro Ala
 20 25 30
 Asp Met Gln Lys Ile Ala Glu Arg Gln Ser Gln Asn Lys Leu Arg His
 35 40 45
 Gly Asn Met Asn Arg Arg Gly Val Glu Asp Asp Leu Ala Gly Glu Glu
 50 55 60
 Ile Gly Val Thr Phe Pro Leu Asp Met Lys Met Thr Gln Glu Gln Phe
 65 70 75 80
 Gln Lys Gln Arg Ala Ala Val Gln Asp Phe Leu Tyr Ser Ser Leu Leu
 85 90 95
 Ser Leu Gly Ser Val Gln Asp Thr Glu Asp Lys Asn Glu Asn Pro Gln
 100 105 110
 Ser Gln

20/25

<210> 34

<211> 82

<212> PRT

<213> Oncorhynchus mykiss

<223> Amino acid sequence for prepro-form of rainbow trout endogenous peptides (23 amino acids) of growth hormone secretagogue

<400>34

```

Met Ile Leu Met Leu Cys Thr Leu Ala Leu Trp Ala Lys Ser Val Ser
 1             5             10             15
Ala Gly Ser Ser Phe Leu Ser Pro Ser Gln Lys Pro Gln Val Arg Gln
          20             25             30
Gly Lys Gly Lys Pro Pro Arg Val Gly Arg Arg Asp Ile Glu Ser Phe
          35             40             45
Ala Glu Leu Phe Glu Gly Pro Leu His Gln Glu Asp Lys His Asn Thr
          50             55             60
Ile Lys Ala Pro Phe Glu Met Gly Ile Thr Met Ser Glu Glu Glu Phe
          65             70             75             80
Gln Glu

```

<210> 35

<211> 99

<212> PRT

<213> Oncorhynchus mykiss

<223> Amino acid sequence for prepro-form of rainbow trout endogenous peptides (20 amino acids) of growth hormone secretagogue

<400>35

```

Met Ile Leu Met Leu Cys Thr Leu Ala Leu Trp Ala Lys Ser Val Ser
 1             5             10             15
Ala Gly Ser Ser Phe Leu Ser Pro Ser Gln Lys Pro Gln Gly Lys Gly
          20             25             30
Lys Pro Pro Arg Val Gly Arg Arg Asp Ile Glu Ser Phe Ala Glu Leu
          35             40             45
Phe Glu Gly Pro Leu His Gln Glu Asp Lys His Asn Thr Ile Lys Ala
          50             55             60
Pro Phe Glu Met Gly Ile Thr Met Ser Glu Glu Glu Phe Gln Glu Tyr

```

21/25

65 70 75 80
 Gly Ala Val Leu Gln Lys Ile Leu Gln Asp Val Leu Gly Asp Thr Ala
 85 90 95
 Thr Ala Glu

<210> 36

<211> 503

<212> DNA

<220>

<221> CDS

<222> (66)... (389)

<213> *Anguilla japonica*

<223> Base sequence of cDNA coding prepro-form of eel endogenous peptides
 of growth hormone secretagogue

<400> 36

ttcaagaggc acigggtttc cttctaaagt gcaaaactcc actgtgagct tcagacaatga 60

ggcag atg aaa cgc acc gca tac atc atc ctg ctg gtc tgc gtc ctg 107
 Met Lys Arg Thr Ala Tyr Ile Ile Leu Leu Val Cys Val Leu

1 5 10

gcg ctg tgg atg gac tct gtc cag gct ggc tcc agc ttc ctc agc ccc 155
 Ala Leu Trp Met Asp Ser Val Gln Ala Gly Ser Ser Phe Leu Ser Pro
 15 20 25 30

tca cag aga ccg cag ggg aag gat aag aag cct ccc agg gtt ggc aga 203
 Ser Gln Arg Pro Gln Gly Lys Asp Lys Lys Pro Pro Arg Val Gly Arg
 35 40 45

cga gac tca gat ggg atc ctg gac ctg ttt atg agg ccc cca ttg cag 251
 Arg Asp Ser Asp Gly Ile Leu Asp Leu Phe Met Arg Pro Pro Leu Gln
 50 55 60

gat gaa gac atc aga cac att acg ttt aac act cct ttt gag atc ggg 299
 Asp Glu Asp Ile Arg His Ile Thr Phe Asn Thr Pro Phe Glu Ile Gly
 65 70 75

atc acc atg act gag gag ctg ttc cag caa tat gga gaa gtg atg cag 347
 Ile Thr Met Thr Glu Glu Leu Phe Gln Gln Tyr Gly Glu Val Met Gln
 80 85 90

aag atc atg cag gat ttg ctg atg gac aca cct gcc aaa gag 389

Lys Ile Met Gln Asp Leu Leu Met Asp Thr Pro Ala Lys Glu

95

100

105

tgacaagagt ggatgatc tggacttcat aaaacctgc gtcccatata ttctgcatt 449

atlgcatgca taattcaacc aatigtlaaa catltaataa aattttgcaa acgc 503

<210> 37

<211> 484

<212> DNA

<220>

<221> CDS

<222> (47)... (388)

<213> *Xenopus laevis*

<223> Base sequence of cDNA coding prepro-form of frog
(*Xenopus laevis*) endogenous peptides of growth hormone
secretagogue

<400> 37

tttaccittt atctgcagg cggcaccggt gaccaggacc ttacagg 46

atg aat ttt ggt aaa gcc gcc atc ttt ggg gtt glc ttg ttc tgc ctg 94

Met Asn Phe Gly Lys Ala Ala Ile Phe Gly Val Val Leu Phe Cys Leu

1

5

10

15

ctg tgg acg gag ggg gcc cag gct ggc ttg acc ttc ctg agt cca gcc 142

Leu Trp Thr Glu Gly Ala Gln Ala Gly Leu Thr Phe Leu Ser Pro Ala

20

25

30

gac atg cag aag att gcg gag agg caa tca cag aat aag ctg aga cac 190

Asp Met Gln Lys Ile Ala Glu Arg Gln Ser Gln Asn Lys Leu Arg His

35

40

45

ggc aat atg aat cgc agg ggt glg gag gat gac ctg gcc ggg gag gag 238

Gly Asn Met Asn Arg Arg Gly Val Glu Asp Asp Leu Ala Gly Glu Glu

50

55

60

atc ggg glg acc ttc cct ctg gat atg aag atg acg cag gag cag ttc 286

Ile Gly Val Thr Phe Pro Leu Asp Met Lys Met Thr Gln Glu Gln Phe

65

70

75

80

cag aag cag agg gct gcg glg cag gac ttc ctg tac tcc tcc ctc ctc 334

Gln Lys Gln Arg Ala Ala Val Gln Asp Phe Leu Tyr Ser Ser Leu Leu

85

90

95

23/25

tct ctc ggg tca gtc cag gat aca gaa gac aag aat gaa aat cct cag 382
 Ser Leu Gly Ser Val Gln Asp Thr Glu Asp Lys Asn Glu Asn Pro Gln
 100 105 110
 agc caa tgagaatgat gaaaatccgc tgcctcctga tgcctcctcc cgaatcgtgt 438
 Ser Gln

gtctttatta tctcgtgta acccagaaat aaatcttatt tatggc 484

<210> 38

<211> 462

<212> DNA

<220>

<221> CDS

<222> (12)... (257)

<213> Oncorhynchus mykiss

<223> Base sequence of cDNA coding prepro-form of rainbow trout endogenous peptides (23 amino acids) of growth hormone secretagogue

<400> 38

tcacaggtct c atg ata ctg atg ctg tgt act ctg gct ctg tgg gcc 47
 Met Ile Leu Met Leu Cys Thr Leu Ala Leu Trp Ala
 1 5 10
 aag tca gtc agt gct ggc tcc agc ttc ctc agc ccc tcc cag aaa cca 95
 Lys Ser Val Ser Ala Gly Ser Ser Phe Leu Ser Pro Ser Gln Lys Pro
 15 20 25
 cag gta aga cag ggt aaa ggg aag ccc cct cga gtt ggt cgg cga gac 143
 Gln Val Arg Gln Gly Lys Gly Lys Pro Pro Arg Val Gly Arg Arg Asp
 30 35 40
 att gag agc ttt gct gag ctg ttt gag ggt ccc ctt cac cag gaa gac 191
 Ile Glu Ser Phe Ala Glu Leu Phe Glu Gly Pro Leu His Gln Glu Asp
 45 50 55 60
 aaa cac aat acg atc aag gct cct ttt gag atg ggc atc acc atg agt 239
 Lys His Asn Thr Ile Lys Ala Pro Phe Glu Met Gly Ile Thr Met Ser
 65 70 75
 gag gag gag ttc cag gag tatgggtccg tgctgcagaa gatcctgcag 287
 Glu Glu Glu Phe Gln Glu
 80

acigigigaa calcgittga atiglaaaag atgaataaaa taacacigct tccit

453

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04907

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁷ C07K14/47, C12N15/12, C12N1/21, C12P21/02, C07K16/18, A61K38/18, A61P5/06, A61P19/08, A61K45/00, A61K48/00, G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁷ C07K14/47, C12N15/12, C12N1/21, C12P21/02, C07K16/18, A61K38/18, A61P5/06, A61P19/08, A61K45/00, A61K48/00, G01N33/53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ/GeneSeq, CA (STN), REGISTRY (STN), WPI (DIALOG), BIOSIS (DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, 98/42840, A1 (ZYMOGENETICS, INC.), 01 October, 1998 (01.10.98), p.19, pp.54-58 & AU, 9865769, A & NO, 9904614, A & EP, 975760, A1 & BR, 9808059, A & CN, 1254375, A	1-32, 40-53
X	BLUET-PAJOT, M-T. et al., "Hypothalamic and hypophyseal regulation of growth hormone secretion", Cellular and Molecular Neurobiology (1998), Vol.18, No.1 pp.101-104, p.109	1, 5, 33-36, 39, 54, 56
P, X	KOJIMA, M. et al., Ghrelin is a growth-hormone-releasing acylated peptide from stomach", NATURE (Dec.1999), Vol.402, No.9, pp.656-660	1-36, 39-54, 56
P, X	HOSODA, H. et al., "Purification and characterization of rat des-Gln ¹⁴ -Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor", J. Biol. Chem. (MAY, 2000), Vol.275, No.29, pp.21995-22000	1-36, 39-54, 56
P, X	WO, 99/63088, A2 (GENENTECH, INC.),	1-32, 40-53

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search
17 October, 2000 (17.10.00)

Date of mailing of the international search report
24 October, 2000 (24.10.00)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04907

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	09 December, 1999 (09.12.99), & AU, 9943286	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04907

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 37-39,55,57
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 37, 38, 55 and 57 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

A. 発明の属する分野の分類 (国際特許分類 (IPC)) Int Cl ⁷ C07K14/47, C12N15/12, C12N1/21, C12P21/02, C07K16/18, A61K38/18, A61P5/06, A61P19/08, A61K45/00, A61K48/00, G01N33/53		
B. 調査を行った分野 調査を行った最小限資料 (国際特許分類 (IPC)) Int Cl ⁷ C07K14/47, C12N15/12, C12N1/21, C12P21/02, C07K16/18, A61K38/18, A61P5/06, A61P19/08, A61K45/00, A61K48/00, G01N33/53		
最小限資料以外の資料で調査を行った分野に含まれるもの		
国際調査で使用了電子データベース (データベースの名称、調査に使用した用語) SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ/GeneSeq, CA (STN), REGISTRY (STN), WPI (DIALOG), BIOSIS (DIALOG)		
C. 関連すると認められる文献		
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
X	WO, 98/42840, A1 (ZYMOGENETICS, INC.) 1. 10月. 1998 (01. 10. 98) p. 19, p54-58 &AU, 9865769, A &NO, 9904614, A &EP, 975760, A1 &BR, 9808059, A &CN, 1254375, A	1-32, 40-53
X	BLUET-PAJOT, M-T. et al. "Hypothalamic and hypophyseal regulation of growth hormone secretion", Cellular and Molecular Neurobiology (1998)第18巻, 第1号 p. 101-104, 109	1, 5, 33-36, 39, 54, 56
<input checked="" type="checkbox"/> C欄の続きにも文献が列挙されている。 <input type="checkbox"/> パテントファミリーに関する別紙を参照。		
* 引用文献のカテゴリー 「A」特に関連のある文献ではなく、一般的技術水準を示すもの 「E」国際出願日前の出願または特許であるが、国際出願日以後に公表されたもの 「L」優先権主張に疑義を提起する文献又は他の文献の発行日若しくは他の特別な理由を確立するために引用する文献 (理由を付す) 「O」口頭による開示、使用、展示等に言及する文献 「P」国際出願日前で、かつ優先権の主張の基礎となる出願日の後に公表された文献 「T」国際出願日又は優先日後に公表された文献であって出願と矛盾するものではなく、発明の原理又は理論の理解のために引用するもの 「X」特に関連のある文献であって、当該文献のみで発明の新規性又は進歩性がないと考えられるもの 「Y」特に関連のある文献であって、当該文献と他の1以上の文献との、当業者にとって自明である組合せによって進歩性がないと考えられるもの 「&」同一パテントファミリー文献		
国際調査を完了した日 17. 10. 00	国際調査報告の発送日 24.10.00	
国際調査機関の名称及びあて先 日本国特許庁 (ISA/J P) 郵便番号100-8915 東京都千代田区霞が関三丁目4番3号	特許庁審査官 (権限のある職員) 六笠 紀子 電話番号 03-3581-1101 内線 3448	4B 9735

C (続き) . 関連すると認められる文献		
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
P, X	KOJIMA, M. et al. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach", NATURE (Dec. 1999) 第402巻, 第9号 p. 656-660	1-36, 39-54, 56
P, X	HOSODA, H. et al. "Purification and characterization of rat des -Gln"-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor", J. Biol. Chem. (MAY, 2000) 第275巻, 第29号 p. 21995-22000	1-36, 39-54, 56
P, X	WO, 99/63088, A2 (GENENTECH, INC.) 9. 12月. 1999 (09. 12. 99) &AU, 9943286	1-32, 40-53

第I欄 請求の範囲の一部の調査ができないときの意見 (第1ページの2の続き)

法第8条第3項 (PCT 17条(2)(a)) の規定により、この国際調査報告は次の理由により請求の範囲の一部について作成しなかった。

1. ☒ 請求の範囲 37, 38, 55, 57 は、この国際調査機関が調査をすることを要しない対象に係るものである。
つまり、
請求の範囲 37、38、55 及び 57 は、人の身体の治療による処置方法であるから、
この国際調査機関が調査をすることを要しない対象に係るものである。
2. ☐ 請求の範囲 は、有意義な国際調査をすることができる程度まで所定の要件を満たしていない国際出願の部分に係るものである。つまり、
3. ☐ 請求の範囲 は、従属請求の範囲であって PCT 規則 6.4(a) の第2文及び第3文の規定に従って記載されていない。

第II欄 発明の単一性が欠如しているときの意見 (第1ページの3の続き)

次に述べるようにこの国際出願に二以上の発明があるとこの国際調査機関は認めた。

1. ☐ 出願人が必要な追加調査手数料をすべて期間内に納付したので、この国際調査報告は、すべての調査可能な請求の範囲について作成した。
2. ☐ 追加調査手数料を要求するまでもなく、すべての調査可能な請求の範囲について調査することができたので、追加調査手数料の納付を求めなかった。
3. ☐ 出願人が必要な追加調査手数料を一部のみしか期間内に納付しなかったため、この国際調査報告は、手数料の納付のあった次の請求の範囲のみについて作成した。
4. ☐ 出願人が必要な追加調査手数料を期間内に納付しなかったため、この国際調査報告は、請求の範囲の最初に記載されている発明に係る次の請求の範囲について作成した。

追加調査手数料の異議の申立てに関する注意

- ☐ 追加調査手数料の納付と共に出願人から異議申立てがあった。
☐ 追加調査手数料の納付と共に出願人から異議申立てがなかった。

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)